Related Experiment Video
Updated: Feb 6, 2026
07:23
Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells
Published on: May 30, 2025
1.2K
Non-coding RNAs in cancer diagnosis and therapy
Mahmood Rasool1, Arif Malik2, Sara Zahid2
1Center of Excellence in Genomic Medicine Research (CEGMR), King Abdulaziz University, Jeddah, Saudi Arabia.
Non-Coding RNA Research
|August 31, 2018
Summary
Non-coding RNAs (ncRNAs) are key regulators of gene expression in cancer metastasis. Research highlights their diagnostic and therapeutic potential in targeting multiple oncogenic pathways for improved cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cancer metastasis involves complex, heterogeneous steps dependent on multiple oncogenic pathways.
- Targeted therapies are evolving to address these complex pathways.
- Previously non-functional genomic regions are now recognized for their role in gene regulation.
Purpose of the Study:
- To review the role of non-coding transcription in cancer metastasis.
- To highlight the clinical relevance, mechanisms, and therapeutic potential of non-coding RNAs (ncRNAs).
- To provide insights into ncRNAs as diagnostic biomarkers and therapeutic agents.
Main Methods:
- Literature review focusing on non-coding RNAs in cancer metastasis.
- Analysis of current research on long non-coding RNAs (lncRNAs) and microRNAs (miRNAs).
- Examination of the biogenesis and mechanisms of ncRNAs in oncogenesis.
Main Results:
- Non-coding RNAs (ncRNAs), including long non-coding RNAs (lncRNAs) and microRNAs (miRNAs), are critical regulators of gene expression.
- ncRNAs exhibit distinct expression profiles in benign versus metastatic tumors.
- miRNAs can reprogram multiple oncogenic cascades, offering therapeutic targets.
Conclusions:
- ncRNAs play a significant role in cancer pathogenesis and metastasis.
- Further clinical research into ncRNA biogenesis and mechanisms can lead to novel diagnostic biomarkers and therapeutic strategies.
- Targeting ncRNAs presents a promising avenue for developing advanced cancer therapeutics.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
10.0K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.0K
02:39lncRNA - Long Non-coding RNAs
3.7K
3.7K
02:30siRNA - Small Interfering RNAs
18.7K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.7K
02:49Cancer Therapies
10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K
02:57piRNA - Piwi-interacting RNAs
7.7K
PIWI-interacting RNAs, or piRNAs, are the most abundant short non-coding RNAs. More than 20,000 genes have been found in humans that code for piRNAs while only 2000 genes have been found for miRNAs. piRNAs can act at the transcriptional and post-transcriptional levels and have a vital role in silencing transposable elements present in germ cells. They are also involved in epigenetic silencing and activation. Previously, they were thought to function only in germ cells but new evidence suggests...
7.7K
02:57Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K